Citalopram/pipamperone

Last updated

Citalopram/pipamperone
Citalopram structure.svg
Citalopram
Pipamperone.svg
Pipamperone
Combination of
Citalopram Selective serotonin reuptake inhibitor
Pipamperone Antipsychotic; Serotonin 5-HT2A receptor antagonist; Dopamine D2 receptor antagonist
Clinical data
Other namesPipCit; PNB-01; PNB01; Pipamperone/citalopram
Routes of
administration 		Oral [1]

Citalopram/pipamperone (developmental code names PipCit, PNB-01) is a combination of citalopram, a selective serotonin reuptake inhibitor (SSRI) and antidepressant, and low-dose pipamperone, an antipsychotic, which is or was under development for the treatment of major depressive disorder. [1] [2] [3] [4] [5] At the low doses used in the combination, pipamperone is said to act as a selective serotonin 5-HT2A and dopamine D4 receptor antagonist, and is thought might accelerate or augment the antidepressant effects of citalopram. [3] [5] The combination is or was being developed by PharmaNeuroBoost. [1] [2] As of September 2015, no recent development has been reported. [1] [2] It reached phase 3 clinical trials. [1] [2]

See also

References

  1. 1 2 3 4 5 "Citalopram/pipamperone". AdisInsight. 1 September 2015. Retrieved 28 February 2025.
  2. 1 2 3 4 "Delving into the Latest Updates on Citalopram Hydrobromide/Pipamperone Hydrochloride with Synapse". Synapse. 23 January 2025. Retrieved 28 February 2025.
  3. 1 2 Wade AG, Crawford GM, Nemeroff CB, Schatzberg AF, Schlaepfer T, McConnachie A, et al. (October 2011). "Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response" (PDF). Psychological Medicine. 41 (10): 2089–2097. doi:10.1017/S0033291711000158. PMID   21349239.
  4. ↑ Buntinx E, Peremans K, Schlaepfer T, Audenaert K, De Spiegeleer B, Megens A (July 2008). "Preclinical and clinical evidence for the efficacy of pipamperone in augmenting the antidepressant effects of the SSRI citalopram". The International Journal of Neuropsychopharmacology. 11: 190.
  5. 1 2 Wade A, Nemeroff C, Schatzberg A, Schlaepfer T, Haazen L, Buntinx E (2010). "P03-383 - Addition of a Selective 5-HT 2A /D 4 Antagonist Accelerates the Antidepressant Effects of Citalopram". European Psychiatry. 25 (S1). doi:10.1016/S0924-9338(10)70989-5. ISSN   0924-9338.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.